# NTM-LD Treatment Based on GenSeizer Characteristic Gene Capture Strategy

> **NCT03224065** · NA · UNKNOWN · sponsor: **Shanghai Pulmonary Hospital, Shanghai, China** · enrollment: 246 (estimated)

## Conditions studied

- Non - Tuberculosis Mycobacteria Lung Disease

## Interventions

- **DIAGNOSTIC_TEST:** Genotype detected through GenSeizer high-throughput gene capture technology

## Key facts

- **NCT ID:** NCT03224065
- **Lead sponsor:** Shanghai Pulmonary Hospital, Shanghai, China
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-10-09
- **Primary completion:** 2020-09-30
- **Final completion:** 2020-09-30
- **Target enrollment:** 246 (ESTIMATED)
- **Last updated:** 2019-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03224065

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03224065, "NTM-LD Treatment Based on GenSeizer Characteristic Gene Capture Strategy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03224065. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*